309 related articles for article (PubMed ID: 24221832)
1. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Canestaro WJ; Patrick AR; Avorn J; Ito K; Matlin OS; Brennan TA; Shrank WH; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):724-31. PubMed ID: 24221832
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Harrington AR; Armstrong EP; Nolan PE; Malone DC
Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Wisløff T; Hagen G; Klemp M
Pharmacoeconomics; 2014 Jun; 32(6):601-12. PubMed ID: 24715603
[TBL] [Abstract][Full Text] [Related]
6. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
8. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Rognoni C; Marchetti M; Quaglini S; Liberato NL
Clin Drug Investig; 2014 Jan; 34(1):9-17. PubMed ID: 24135964
[TBL] [Abstract][Full Text] [Related]
9. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Verhoef TI; Redekop WK; Hasrat F; de Boer A; Maitland-van der Zee AH
Am J Cardiovasc Drugs; 2014 Dec; 14(6):451-62. PubMed ID: 25326294
[TBL] [Abstract][Full Text] [Related]
11. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Pink J; Pirmohamed M; Lane S; Hughes DA
Clin Pharmacol Ther; 2014 Feb; 95(2):199-207. PubMed ID: 24067746
[TBL] [Abstract][Full Text] [Related]
13. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Desai NR; Krumme AA; Schneeweiss S; Shrank WH; Brill G; Pezalla EJ; Spettell CM; Brennan TA; Matlin OS; Avorn J; Choudhry NK
Am J Med; 2014 Nov; 127(11):1075-1082.e1. PubMed ID: 24859719
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Wang Y; Xie F; Kong MC; Lee LH; Ng HJ; Ko Y
Cardiovasc Drugs Ther; 2014 Dec; 28(6):575-85. PubMed ID: 25319314
[TBL] [Abstract][Full Text] [Related]
15. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Kansal AR; Zheng Y; Pokora T; Sorensen SV
Best Pract Res Clin Haematol; 2013 Jun; 26(2):225-37. PubMed ID: 23953910
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.
Krejczy M; Harenberg J; Marx S; Obermann K; Frölich L; Wehling M
J Thromb Thrombolysis; 2014 May; 37(4):507-23. PubMed ID: 24221805
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Liu CY; Chen HC
Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Shah A; Shewale A; Hayes CJ; Martin BC
Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
